From initial consultation to ongoing care, our team can guide you through the process
Injection site: subcutaneous, abdomen
3.2 Lactoferrin activates IRS-1/PI3K/AKT to improve insulin resistance Studies have shown that LF upregulates insulin receptor (IR), insulin receptor substrate-1 (IRS-1), glucose transporter 4 (GLUT4), PI3K and AKT in liver protein expression (30), increases peroxisome proliferator-activated receptor and regulatory protein SIRT-1 expression (28), and is negatively correlated with chronic inflammation-induced metabolic disorders of insulin resistance, hyperglycemia, and obesity, and positively correlated with insulin sensitivity (48)
Cancer & Immune System Evasion (02:00:09) Checkpoint Inhibitors, CTLA-4 (02:06:45) Anti-CTLA-4 Study Drug (Ipilimumab), Melanoma (02:12:07) Patient Population, Randomization, GP100 (02:18:09) Response Rate (02:22:52) Overall Survival & Response (02:28:38) Median Survival vs